Shenzhen - Delayed Quote CNY

Tus-Pharmaceutical Group Co., Ltd. (000590.SZ)

9.75
+0.02
+(0.21%)
At close: May 23 at 3:04:27 PM GMT+8
Loading Chart for 000590.SZ
  • Previous Close 9.73
  • Open 9.07
  • Bid 9.73 x --
  • Ask 9.74 x --
  • Day's Range 9.63 - 10.08
  • 52 Week Range 4.82 - 10.10
  • Volume 9,565,200
  • Avg. Volume 7,257,398
  • Market Cap (intraday) 2.335B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.56
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jun 21, 2013
  • 1y Target Est --

Tus-Pharmaceutical Group Co., Ltd. manufactures and sells Chinese patent medicines, chemical medicines, and health foods in China. It offers prescription and over-the-counter drugs, such as tonic and health care, cardiovascular and cerebrovascular, children's nutrition, cold, and heat-clearing and detoxifying drugs. The company was formerly known as Tus-Guhan Group Corp.,Ltd. Tus-Pharmaceutical Group Co., Ltd. was founded in 1956 and is headquartered in Hengyang, China.

www.tuspharma.cn

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 000590.SZ

View More

Performance Overview: 000590.SZ

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

000590.SZ
37.13%
SSE Composite Index (000001.SS)
0.10%

1-Year Return

000590.SZ
46.40%
SSE Composite Index (000001.SS)
7.44%

3-Year Return

000590.SZ
21.12%
SSE Composite Index (000001.SS)
6.40%

5-Year Return

000590.SZ
0.71%
SSE Composite Index (000001.SS)
19.00%

Compare To: 000590.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 000590.SZ

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    2.33B

  • Enterprise Value

    2.32B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.05

  • Price/Book (mrq)

    4.01

  • Enterprise Value/Revenue

    7.00

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -36.56%

  • Return on Assets (ttm)

    -1.13%

  • Return on Equity (ttm)

    -19.14%

  • Revenue (ttm)

    343.21M

  • Net Income Avi to Common (ttm)

    -125.47M

  • Diluted EPS (ttm)

    -0.56

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    144.95M

  • Total Debt/Equity (mrq)

    22.31%

  • Levered Free Cash Flow (ttm)

    -2.02M

Research Analysis: 000590.SZ

View More

Company Insights: 000590.SZ

Research Reports: 000590.SZ

View More

People Also Watch